Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size

Impact of the initial administration of an antiretroviral drug with latency reversal properties on the HIV reservoir size

Abstract The elimination of the latent viral reservoir remains the main barrier in the quest for a cure for people with HIV (PWH). The administration of latency reversal agents (LRA) at antiretroviral treatment (ART) initiation could improve the effectiveness of strategies aimed at HIV remission. Th...

Full description

Saved in:
Bibliographic Details
Main Authors: Erick De La Torre Tarazona, Elisa Moraga, Raúl Vaquer, Sonsoles Sánchez-Palomino, Elisa de Lazzari, Laura Luna, Sònia Vicens-Artés, Lucio Jesús García Fraile, Joaquim Peraire, Mercedes Garcia-Gasalla, Luz Balsalobre, Sergio Guillén Martínez, Luis Fernando López Cortés, Inma Jarrín, Sergio Serrano-Villar, José Alcamí, Santiago Moreno, CoRIS Cohort
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Latency reversal agent
Timing of administration
HIV reservoir
Maraviroc
Antiretroviral Therapy
Online Access:https://doi.org/10.1038/s41598-025-09474-1
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract The elimination of the latent viral reservoir remains the main barrier in the quest for a cure for people with HIV (PWH). The administration of latency reversal agents (LRA) at antiretroviral treatment (ART) initiation could improve the effectiveness of strategies aimed at HIV remission. This study assessed the impact of maraviroc (MVC), an antiretroviral drug with HIV latency reversal properties, on the viral reservoir size when it is administered at ART initiation. We conducted a longitudinal observational study in PWH initiating ART with a regimen including (MVC-initiation, n = 12) or not including MVC (non-MVC-initiation, n = 22), or switching to an MVC-containing regimen after achieving an undetectable viral load (VL) (MVC-switch, n = 9). The HIV reservoir size was determined via Alu-LTR and Intact Proviral DNA Assay (IPDA) methods, and cell-associated HIV-RNA (ca-HIV-RNA) by nested-qPCR. Comparative analyses employed mixed multivariate linear models. After a median of 90 weeks, the MVC-initiation group showed a greater reduction in integrated and IPDA-total (7.1- and 4.0-fold, respectively), but not IPDA-intact, HIV-DNA reservoir compared to the non-MVC-initiation group. The reductions in integrated, IPDA-total, and IPDA-intact HIV-DNA levels in the MVC-initiation group were also greater compared to the MVC-switch group (from 5.4 to 13.8-fold). Moreover, no significant differences in the HIV transcriptional activity, assessed by ca-HIV-RNA levels or HIV-RNA/HIV-DNA ratios, were observed between the MVC-initiation and non-MVC-initiation groups. In conclusion, starting ART with a drug with HIV latency reversing activity at detectable VL phase may contribute to a greater reduction in the HIV-DNA reservoir. These findings could inform the design of future trials targeting HIV remission via a “kick and kill” strategy.
ISSN:2045-2322

Similar Items